1Peep V,David E,Gunvor-von W,et al.Intravitreal bevacizumab in central retinal vein occlusion:18-month results of a prospective clinical trial[J].Eur J Ophthalmol,2011,21:789-795.
2Gilbert C, Rahi J, Eckstein M, et a l. Retinopathy of prematurity in middle - income countries[J].Lancet, 1997,350 :12 - 14.
3Flynn JT, Chan - Ling T. Retinopathy of prematurity : Two distinct mechanisms that underline zone 1 and zone 2 disease[J]. Am J Ophthalmology, 2006,142 : 46 - 59.
4Mintz - Hittner HA,Kuffel RR Jr. Intravitreal injection of bevacizumab(avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II[J]. Retina,2008,28(6) :831 -838.
5Quiroz - Mercado H, Martinez - Castellanos MA, Hernandez - Rojas ML,et al. Antiangiogenic therapy with intravitreat bevacizumab for retinopathy of prematurity[J]. Retina, 2008,28 (3 Suppl) : 19 - 25.
6Lalwani GA, Berrocal AM, Murray TG,et al. Off - label use of in travitreal bevaclzumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity[J]. Retina, 2009,29 (1) : 127.
7Spitzer MS, Wallenfels - Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells [J]. Br J Ophthalmol,2006,90(10) :1316 - 1321.
8Micieli JA,Surkont M,Smith AF. A systematic analysis of the off- label use of bevacizumab for severe retinopathy of prematurity [J]. Am J Ophthalmol, 2009,148(4) : 536 - 543.
9Age Related Eye Disease Study Research Group.A randomized,placebo-controlled,clinical trial of high-dose supplementation withvitamins C and E,beta carotene,and zinc for age-related maculardegeneration and vision loss:AREDS Report no.8.Arch Ophthalmol2001;119(10):1417-1436.
10Rosenfeld PJ,Moshfeghi AA,Puliafito CA.Opticalcoherencetomography findings after an intravitreal injection ofbevacizumab(Avastin)for neovascularization age-related maculardegeneration.Ophthalmic Surg Lasers Imaging 2005;36(4):331-335.
